Wang Lu, Wang Yinglin, Zhao Quan
Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, 264000, Shandong Province, China.
BMC Nephrol. 2024 Dec 18;25(1):465. doi: 10.1186/s12882-024-03901-7.
Chronic kidney disease is a significant public health issue. Dapagliflozin has been shown to improve the quality of life for patients with chronic kidney disease. This review aimed to systematically assess the cost-effectiveness of adding dapagliflozin to standard care compared with standard care alone for treating chronic kidney disease.
The relevant studies were searched in PubMed, Web of Science, Scopus, Embase, and Cochrane from the inception date to June 1, 2024. The titles, abstracts, and full texts were independently evaluated and screened by two authors. Additionally, the economic evaluation studies were assessed independently by two authors using the consolidated health economic evaluation reporting standards checklist.
14 studies were included which were about the economic evaluations of adding dapagliflozin in the treatment of chronic kidney disease. The minimum consolidated health economic evaluation reporting standards score for the studies was 0.77, indicating very good quality. Adding dapagliflozin to the standard of care would be more effective and cost-saving in Mexico, Malaysia, Canada, Thailand, and China. The highest incremental cost-effectiveness ratio of dapagliflozin ($67962.75/QALY) originated from the USA. According to the available studies, adding dapagliflozin to standard of care for the treatment of chronic kidney disease is considered cost-effectiveness from both the healthcare system and the payer's perspective.
Adding dapagliflozin to standard care in the treatment of chronic kidney disease is cost-effective from both the healthcare system and the payer's perspective in well-developed countries.
慢性肾脏病是一个重大的公共卫生问题。已证明达格列净可改善慢性肾脏病患者的生活质量。本综述旨在系统评估与单纯标准治疗相比，在标准治疗中添加达格列净治疗慢性肾脏病的成本效益。
从创刊日期至2024年6月1日，在PubMed、科学网、Scopus、Embase和Cochrane中检索相关研究。由两位作者独立评估和筛选标题、摘要和全文。此外，两位作者使用统一的卫生经济评估报告标准清单独立评估经济评估研究。
纳入了14项关于在慢性肾脏病治疗中添加达格列净的经济评估研究。这些研究的最低统一卫生经济评估报告标准评分为0.77，表明质量非常好。在墨西哥、马来西亚、加拿大、泰国和中国，在标准治疗中添加达格列净将更有效且节省成本。达格列净的最高增量成本效益比（67962.75美元/质量调整生命年）来自美国。根据现有研究，从医疗系统和支付方的角度来看，在标准治疗中添加达格列净治疗慢性肾脏病被认为具有成本效益。
从医疗系统和支付方的角度来看，在发达国家，在慢性肾脏病治疗的标准治疗中添加达格列净具有成本效益。
